Literature DB >> 24342929

Apparently "low" serum asymmetric dimethylarginine is associated with fasting glucose and tends toward association with type-2 diabetes.

Altan Onat1, Bayram Köroğlu, Günay Can, Ahmet Karagöz, Murat Yüksel, Mesut Aydın.   

Abstract

OBJECTIVE: We investigated the association of serum asymmetric dimethylarginine (ADMA) with metabolic syndrome (MetS), type-2 diabetes and coronary heart disease (CHD) in the general population.
METHODS: Cross-sectional and, at 2000 person-years' follow-up, prospective analysis. Adults with measured serum ADMA level (n=848) were analyzed using tertiles or dichotomized values. ADMA concentrations were measured by a validated commercial ELISA kit.
RESULTS: Dichotomized subjects of combined sexes with low (≤0.68 µmol/L) ADMA values had significantly higher fasting glucose, total cholesterol, apolipoprotein B and lower diastolic blood pressure. In linear regression analyses comprising age, smoking, triglyceride, HDL-cholesterol, C-reactive protein and waist circumference as well, creatinine was significantly and independently associated with ADMA, further in women glucose (inversely). In logistic regression analyses uniformly adjusted for age, smoking status and waist girth, prevalent MetS tended to positive independent association with ADMA tertiles only in men. Combined prevalent and incident diabetes weakly tended to be associated with the lowest (vs mid- and highest) ADMA tertiles in combined gender; and prevalent and incident CHD was not associated with ADMA tertiles in either sex.
CONCLUSION: Apparently "low" circulating ADMA is independently associated with fasting glucose and tends to be so with type-2 diabetes. The lack of anticipated positive associations of ADMA with cardiometabolic disorders is likely due to autoimmune responses operating against serum ADMA under oxidative stress, rendering partial failure in immunoassay.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24342929     DOI: 10.5152/akd.2013.5009

Source DB:  PubMed          Journal:  Anadolu Kardiyol Derg        ISSN: 1302-8723


  5 in total

1.  Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk.

Authors:  Altan Onat; Mesut Aydın; Günay Can; Etem Çelik; Servet Altay; Ahmet Karagöz; Evin Ademoğlu
Journal:  Endocrine       Date:  2014-05-03       Impact factor: 3.633

2.  ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes.

Authors:  Radosław Wieczór; Anna M Wieczór; Arleta Kulwas; Danuta Rość
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-22

3.  Effectiveness of a standard secondary coronary prevention program: not obligate.

Authors:  Altan Onat
Journal:  Anatol J Cardiol       Date:  2016-02       Impact factor: 1.596

4.  Rheumatoid factor mediates excess serum lipoprotein(a) for independent association with type 2 diabetes in men.

Authors:  Altan Onat; Evin Ademoğlu; Günay Can; Servet Altay; Ahmet Karagöz; Bayram Köroğlu; Hüsniye Yüksel
Journal:  Anatol J Cardiol       Date:  2014-10-31       Impact factor: 1.596

5.  High-normal thyroid-stimulating hormone in euthyroid subjects is associated with risk of mortality and composite disease endpoint only in women.

Authors:  Servet Altay; Altan Onat; Günay Can; Eyyup Tusun; Barış Şimşek; Adnan Kaya
Journal:  Arch Med Sci       Date:  2016-10-26       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.